July 14, 1998
LITTLE ROCK, AR Each year millions of
Americans have no choice but to begin and stay on steroid-type medications for
life-threatening diseases. Such treatments protect those who receive transplants
from rejecting their new organs and help people with chronic conditions such as asthma,
rheumatoid arthritis, ulcerative colitis, multiple sclerosis and some blood and kidney
diseases to have a normal life. Typically, the therapy is needed for many years.
But no matter what the age or gender of these
patients, they all can expect the same side effect from taking steroids--serious bone loss
or so called osteoporosis--a condition that slowly weakens the bones and eventually causes
fractures. More than one-third of patients taking steroids for more than five years
have fractures. For the past 60 years, physicians have known that steroid-induced
osteoporosis is one of the medications side effects, but why it occurs has not been
clear until now.
The Central Arkansas Veterans Healthcare System and
the University of Arkansas for Medical Sciences will co-host a media briefing on
Wednesday, July 15, at 11 a.m. (CST) in the Education III Building, Room 225, on the UAMS
Little Rock campus. The researchers of the UAMS/VAMC Center for Osteoporosis and
Metabolic Bone Diseases who have uncovered how steroids cause osteoporosis will present
their results, as featured in the cover story of the July 15, 1998, issue in the
prestigious Journal of Clinical Investigation, pg. 1-9.
VA Associate Director of Geriatric Research and
Education Clinical Center Stavros C. Manolagas, M.D., Ph.D.UAMS Director of the
Division of Endocrinology and Metabolism and the UAMS/VAMC Center for Osteoporosis--said,
The discoveries described in this paper represent an important breakthrough as they
open the way to tackle a serious medical dilemma that involves millions of people:
how to get the many benefits of steroids without devastating the skeleton.
Basically, our findings revealed that when animals or humans take high doses of steroids,
not only fewer bone-forming cells are made, but they are dying prematurely. This discovery
follows our earlier breakthroughs explaining how women lose bone after menopause and how
both women and men develop osteoporosis with old age. It confirms our general idea
that the fundamental problem in all forms of osteoporosis is abnormal birth and/or death
of bone cells.
Dr. Manolagas went on to say, One very exciting
prospect, now that we know the nature of this particular problem, is the development
of designer-steroids that will have the inflammation combating
properties of the existing steroids but will not have their bone killing effects; in other
words, they will be bone sparing. This idea is similar to what is already a reality in the
case of postmenopausal osteoporosis, where physicians now have available for their
patients designer estrogens that protect the skeleton, but do not have the
breast cancer risk associated with the classical estrogen.
VA Staff Endocrinologist Robert Weinstein, M.D.--UAMS
professor and first author of the paper--explained, Our study shows that
steroid-induced osteoporosis arises from changes in the number of bone cells available to
maintain bone. This disrupts the stability of bone, causing eventual fractures and,
also, collapse of large joints. No bone is spared from the steroid-induced bone loss, but
the effects are more dramatic in the spine and in the hip. Unlike common age- and
gender-related types of osteoporosis, this form of the disease occurs at any age, even in
children. Not infrequently, patients that took steroids for many years end up in a
wheelchair. Yet, a recent survey of physicians, showed that most underestimated the risk
of glucocorticoid-induced osteoporosis in men and women. Only 25 percent ranked
osteoporosis as one of the top three side effects of high-dose glucocorticoid therapy in a
45-year-old pre-menopausal woman and 8 percent ranked it as one of the top three side
effects in a 45-year-old man.
Dr. Weinstein said that, Like all problems,
knowing the cause makes it a lot easier to figure out the proper defense. We got our clues
first from studies with mice. We found that death of bone forming cells was occurring even
in normal bones, but at a very low rate. We were totally amazed when we saw the
devastating effect of steroids on the survival of these cells, in sections of bone under
the microscope. We repeated the findings over and over again to be certain that they were
exactly what we thought we were seeing and there were no quirks in our measurements. We
felt very gratified and relieved when we saw exactly the same thing in biopsies from
patients that had osteoporosis from taking steroids. I am very pleased that, along with
the manuscript that is being published in the Journal of Clinical Investigation, the
editors were excited enough about our photomicrographs from patients that they chose them
for the cover of the Journal.
Two other team members who are co-authors in this
paper, VA Research Scientist Robert Jilka, Ph.D., and UAMS Professor of Medicine Michael
Parfitt, M.D., made important contributions to these studies. Dr. Jilka reproduced
the findings in a cell culture dish and he found that steroids decreased the birth of new
cells. Dr. Parfitt worked out that the rate of cell death caused by steroids was
high enough to have the devastating effect seen in the bones.
Our faculty has made an important discovery
that could impact the well being of millions of people all over the world. It
suggests an approach to the solution of a medical problem that together with the
post-menopausal and age-related form of osteoporosis has reached epidemic
proportions, said UAMS Executive Vice Chancellor and Dean of the College of
Medicine, I. Dodd Wilson, M.D.
Dr. Wilson added, Thanks to the partnership of
the UAMS College of Medicine and the Central Arkansas Veterans Healthcare System, we have
on our campus one of the largest and most successful centers for osteoporosis and
metabolic bone diseases in the country. We are very proud of this.
Through the years, VA research has made major
contributions toward improving healthcare, not only for veterans, but for all
Americans, said Director of the Central Arkansas Veterans Healthcare System, George
H. Gray, Jr. This study demonstrates the commitment of these outstanding
investigators to search for cause, treatment and cure of disease.
# # #
EMBARGOED UNTIL JULY 14, 1998 CST 4 p.m.
CONTACTS:
Central Arkansas Veterans Healthcare System, Sharon Palmer(501)660-2001
UAMS, Bonnie Brandsgaard(501)686-8013 brandsgaardbonniel@exchange.uams.edu
(TV PRODUCERS AND REPORTERS: An animated video, which
illustrates this steroid-induced imbalance in bone maintenance, is available by request in
Beta-SP and S-VHS formats.
PRINT REPORTERS: Color or black-and-white photos of researchers and illustrations are
available.)
BACKGROUND INFORMATION:
-Weighing benefits and risks is part of all medical decisions.
-Loss of bone is one of the fundamental side effects of steroids.
-Bones are constantly rebuilding themselves.
-When people lose more bone than their bodies make, this process is called osteoporosis.
-Osteoporosis is a loss of bone that leads to fragility and accounts for 1.5 million
fractures annually in the United States alone.
-Osteoporosis, porous bone, is the most common bone disease in the world. |